Cizzle Bio, Inc
In the global fight against cancer, timing can mean everything. Early detection often determines whether a disease is treatable or life-threatening. Enter Cizzle Bio, Inc., a forward-thinking biotech firm committed to transforming how cancer is detected—earlier, faster, and more accessibly than ever before.
Founded in 2024 and headquartered in San Antonio, Cizzle Bio is pioneering minimally invasive diagnostic solutions that aim to shift cancer detection from late-stage reaction to early-stage prevention.
A Mission Rooted in Urgency and Impact
At the core of Cizzle Bio’s vision is a simple yet powerful idea: detect cancer when it is most treatable and survivable. Led by Chairman and CEO Bill Behnke, the company is driven by both scientific innovation and a deeply personal commitment to improving patient outcomes.
Cizzle Bio addresses one of healthcare’s most pressing challenges—late diagnosis. Traditional detection methods often identify cancer only after symptoms appear, when treatment options may be limited. By contrast, Cizzle Bio focuses on biomarker-based blood tests that enable detection at the earliest stages.
Breakthrough Science: The Power of Biomarkers
Cizzle Bio’s flagship innovation, the CIZ1B lung cancer test, represents a significant advancement in early detection. Built on over two decades of research at the University of York, the test identifies a unique protein variant in the blood associated with early-stage lung cancer.
What makes this innovation remarkable is its simplicity and effectiveness:
- Requires only a standard blood draw
- Detects cancer at Stage 1
- Enables earlier intervention and improved survival rates
With exclusive licensing rights across North America and the Caribbean, Cizzle Bio is positioning this technology for widespread clinical adoption.
Expanding the Pipeline: Beyond Lung Cancer
Cizzle Bio is not stopping at lung cancer. The company is preparing to launch DEX-G2, a highly advanced diagnostic for gastric cancer developed by the City of Hope Comprehensive Cancer Center.
This test leverages cutting-edge miRNA biomarker technology and has demonstrated an impressive 95% sensitivity for early-stage detection in clinical trials. By combining cell-free and exosomal biomarkers, DEX-G2 represents the next frontier in precision diagnostics.
Collaboration Driving Global Impact
Cizzle Bio’s growth is fueled by partnerships with leading medical institutions, including Moffitt Cancer Center and UT Health San Antonio MD Anderson. These collaborations ensure rigorous validation and accelerate the path to clinical adoption.
The company has also expanded internationally, partnering with Doctors Hospital Cayman, marking its first step toward global accessibility.
Democratizing Access to Early Detection
One of Cizzle Bio’s defining principles is health equity. The company is committed to making early cancer detection accessible regardless of geography, income, or healthcare infrastructure.
By developing affordable, minimally invasive tests, Cizzle Bio aims to:
- Reduce disparities in cancer diagnosis
- Expand access beyond urban medical centers
- Integrate early detection into routine primary care
This mission reflects a broader shift in healthcare—from reactive treatment to proactive prevention.
Innovation Beyond the Lab
Technology plays a central role in scaling Cizzle Bio’s impact. Through its partnership with Tasso, the company is enabling at-home blood sample collection, eliminating barriers to testing and improving patient convenience.
Additionally, ongoing policy advocacy and partnerships with laboratory networks are helping integrate these diagnostics into mainstream healthcare systems.
Leadership with Purpose
For Bill Behnke, the mission is deeply personal. With over 30 years of experience in healthcare innovation, his leadership is shaped not only by professional expertise but also by his family’s journey—his daughter’s early battle with lymphoma.
This experience ignited a lifelong commitment to ensuring that families have access to earlier, more effective diagnostic options. Beyond Cizzle Bio, Bill contributes to the broader oncology community through his involvement with organizations like the Leukemia and Lymphoma Society and the ASCO Foundation.
The Future of Cancer Detection
Cizzle Bio’s vision extends far beyond its current innovations. The company is building a comprehensive pipeline of cancer diagnostics, expanding global partnerships, and working toward reimbursement models that eliminate financial barriers.
Its ultimate goal is transformative:
To make early cancer detection a routine, accessible part of everyday healthcare—not a privilege reserved for a few.
Redefining What’s Possible
Cizzle Bio, Inc. is not just advancing diagnostic technology—it is reshaping the future of cancer care. By combining scientific precision with a mission-driven approach, the company is turning early detection into a powerful tool for saving lives.
In a world where every moment counts, Cizzle Bio is ensuring that those moments come sooner—when they matter most.
